EyePoint Pharmaceuticals

Press Releases

Phase 3 trial of Medidur™ in Posterior Segment Uveitis Meets Enrollment Target
Oct 04, 2016
Study is the Second of Two Ongoing Phase 3 Trials in Support  Of Product Registration in the US EU Filing Remains on Track for 1Q2017 Filing WATERTOWN, Mass. , Oct. 04, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug technologies
pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist
Sep 27, 2016
WATERTOWN, Mass. , Sept. 27, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA),  a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the appointment of Jay S. Duker , M.D, to the Company's Board of Directors.  Dr.
pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference
Sep 22, 2016
WATERTOWN, Mass. , Sept. 22, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that Nancy Lurker , the Company's newly-appointed President and Chief Executive Officer,
pSivida Reports Inducement Awards to New President and Chief Executive Officer
Sep 20, 2016
WATERTOWN, Mass. , Sept. 20, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, today reported the grant of inducement awards to its new President and Chief Executive Officer, Nancy
pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO
Sep 15, 2016
WATERTOWN, Mass. , Sept. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that its Board of Directors has appointed Nancy Lurker as its President and Chief Executive
pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results
Sep 12, 2016
WATERTOWN, Mass. , Sept. 12, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its fourth quarter and fiscal year
pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Sep 01, 2016
WATERTOWN, Mass. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the fourth quarter and fiscal year 2016 will be
pSivida Announces 13 New Patents Issued or Allowed
Aug 29, 2016
U.S. and foreign patents for bioerodible Medidur™, new smaller needle Medidur injector and Tethadur™
Topline Results from First Phase 3 Trial of pSivida's Medidur™ Presented at ASRS Annual Meeting
Aug 15, 2016
WATERTOWN, Mass. , Aug. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that Dr. Glenn J. Jaffe , Robert Machemer Professor of Ophthalmology at Duke University School of
Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle
Aug 09, 2016
Results to Form Part of Planned Applications for Marketing Approvals in EU and US
pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer
Aug 03, 2016
Industry Veteran Brings Over 25 Years of Pharmaceutical and Drug Development Experience
pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis
Aug 01, 2016
WATERTOWN, Mass. and NEW YORK , Aug. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery (HSS), America's leading specialty hospital devoted to orthopedics and
pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)
Jul 27, 2016
Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit
Data Shows pSivida's Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy
Jul 20, 2016
Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society
pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility
Jul 15, 2016
Plan to Facilitate Product Development and Reduce Operating Expenses
Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve
Jul 14, 2016
Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology
pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting
Jul 08, 2016
WATERTOWN, Mass. , July 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that pSivida's Dr. Catherine Kelly will present a poster and oral presentation on "The Controlled
pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD
Jul 05, 2016
Promising Results for Potential Sustained Treatment of Wet AMD Using a TKI
pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
May 05, 2016
WATERTOWN, Mass. , May 05, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31,
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
May 04, 2016
WATERTOWN, Mass. , May 04, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , president and CEO, will present "Changing the Treatment Paradigm
Displaying 41 - 60 of 303
EyePoint Pharmaceuticals